Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging tolerability study of Alpharen in haemodialysis subjects with hyperphosphataemia
2006-004735-30Phase 2Completed
- Sponsor
- INEOS Healthcare Limited
- Start
- Sep 2006
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of sevelamer carbonate in hyperphosphatemia and end-stage kidney disease (ESKD) (2 arms), sponsored by INEOS Healthcare Limited. Primary endpoint: Primary tolerability endpoint. Started Sep 2006; status: completed.
02
Drugs
sevelamer carbonate
03
Conditions
hyperphosphatemiaend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2006-004735-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004735-30.